Cisplatin
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
ATNLYTEPRE
SevereOpen →
Purine analog (ADA inhibitor)
Pentostatin
Nipent · PENT
A renally cleared, dialyzable ADA inhibitor with dose-related AKI — dose strictly by measured CrCl.
ModeratePurine analog (ADA inhibitor) · approved 1991
Alpha-interferon-refractory hairy-cell leukemiaOff-label: chronic lymphocytic leukemia, cutaneous/peripheral T-cell lymphoma, graft-versus-host disease
Signature kidney injury
Acute Tubular Necrosis
At modern low doses clinically significant nephrotoxicity is uncommon and a precise contemporary incidence is not quantified; serious dose-related AKI was historically tied to higher-dose regimens. Tumor lysis can add a secondary AKI mechanism in bulky disease.
Source: Grever et al., J Clin Oncol 1995
Mechanism of kidney injury
Pentostatin is renally cleared and can cause dose-related intrinsic tubular nephrotoxicity and acute renal failure; the precise segment-level human histology is not well characterized but a proximal-tubular ATN pattern is described. Overexposure (from inadequate renal dose reduction) is the main driver, with tumor lysis a secondary contributor.
Clinical presentation
A rising creatinine and uremia, dose-related, emerging during dosing cycles (every 1-2 weeks); watch for concurrent tumor-lysis derangements. Profound, durable T-cell/CD4 lymphopenia predisposes to opportunistic infection.
Onset
During or after dosing cycles; generally reversible with dose reduction or discontinuation.
Reversibility
Reversible
Anticancer mechanism
Tight-binding, essentially irreversible adenosine deaminase (ADA) inhibitor. ADA blockade causes intracellular accumulation of (deoxy)adenosine and dATP, which inhibits ribonucleotide reductase, depletes the dNTP pool, and blocks DNA synthesis and repair while depleting ATP — lymphotoxic to dividing and resting lymphocytes (especially T cells).
Management
Hold or reduce the dose for a rising creatinine; provide supportive care and hydration. In ESKD, deliberate post-infusion hemodialysis has been used to limit exposure. Manage tumor lysis with standard measures.
Risk factors
- Pre-existing renal impairment
- High-dose schedules and overestimated GFR (Cockcroft-Gault) in the critically ill
- Volume depletion and concurrent nephrotoxins
- High tumor burden
Prevention
- CrCl-based dosing using measured renal function
- Hydration and avoidance of concurrent nephrotoxins
- Tumor-lysis prophylaxis in bulky disease
- Do not combine with fludarabine (severe/fatal pulmonary toxicity)
Note · Established (1991) agent; modern low-dose nephrotoxicity is uncommon and not quantified, while CrCl-based dosing and dialyzability are well documented.
Clinical depth
Renal dose adjustment
Renally adjusted: CrCl >60 mL/min ~4 mg/m2 every 14 days (standard); CrCl 41-60 ~3 mg/m2; CrCl 21-40 ~2 mg/m2; CrCl <20-30/severe generally avoid (insufficient data). Even these reductions may overexpose critically ill patients (Cockcroft-Gault overestimates function) — interpret cautiously.
Dialyzability & ESKD dosing
Dialyzable — deliberate post-infusion hemodialysis has been used to limit exposure and permit cautious dosing in ESKD.
Differential diagnosis
Tumor-lysis AKI, prerenal states, concurrent nephrotoxins, combination-therapy toxicity, leukemic infiltration and sepsis-related ATN — versus dose-related intrinsic pentostatin nephrotoxicity from overexposure.
Monitoring
- Creatinine/CrCl before each cycle
- CBC (myelosuppression) and LFTs
- Urate/electrolytes (tumor-lysis screen)
- Infection surveillance (durable CD4 lymphopenia — PJP, CMV)
Key trials & series
- Grever NCI intergroup RCT (J Clin Oncol 1995) — pentostatin superior to interferon in HCL
- Lathia renal PK study (Cancer Chemother Pharmacol 2002) — CrCl-stratified dose reductions
Clinical pearls
- Dose strictly by measured CrCl — Cockcroft-Gault overestimates function in the critically ill and leads to overexposure.
- Pentostatin is dialyzable — deliberate post-infusion hemodialysis allows cautious use in ESKD.
- Do not combine with fludarabine (severe/fatal pulmonary toxicity); avoid high-dose regimens.
- Profound durable T-cell depletion mandates PJP/CMV vigilance beyond the dosing period.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Acute Tubular NecrosisElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of purine analog (ada inhibitor)s.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Mucositis and diarrhea
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis (methotrexate)
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Methotrexate / gemcitabine pneumonitis
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRandomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.Grever M et al. · J Clin Oncol 1995 · PMID 7707126Pivotal NCI intergroup RCT establishing pentostatin superiority over interferon.PMIDLong-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.Flinn IW et al. · Blood 2000 · PMID 11049974Long-term durability and safety follow-up.PMIDMechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.Bontemps F et al. · Cancer Res 1989 · PMID 2788493Mechanism: ADA inhibition drives dATP accumulation and ATP depletion (core lymphotoxicity).PMIDPentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.Lathia C et al. · Cancer Chemother Pharmacol 2002 · PMID 12172976Key renal PK study defining CrCl-stratified dose reductions.PMIDStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Poi MJ et al. · Clin Pharmacokinet 2013 · PMID 23588536Conventional CrCl reductions can still overexpose; caution with Cockcroft-Gault overestimation.PMID[Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis].Arima N et al. · Rinsho Ketsueki 2005 · PMID 16440802Dialyzability/management: reduced-dose pentostatin with post-infusion hemodialysis in ESKD.PMIDAnticancer drug-induced kidney disorders.Kintzel PE et al. · Drug Saf 2001 · PMID 11219485Onconephrology review citing pentostatin dose-related nephrotoxicity/acute renal failure.